Acutaas Chemicals Limited
NSE: ACUTAAS · Pharmaceuticals · sector
₹3,348.80NSE close 2026-10-26
Key numbers
Market cap₹27,417 cr
Price₹3,348.80
52w high / low₹3,740 / ₹1,570
P/E71.0xSector median 27.9x
P/B16.6xSector median 2.9x
Book value₹202.0
Dividend yield0.05%Sector median 0.48%
ROE26.1%Sector median 11.7%
ROCE31.7%Sector median 12.3%
OPM37.1%Sector median 14.0%
Debt / equity0.02xSector median 0.16x
EV/EBITDA50.2xSector median 18.6x
Interest cover141.2x
Current ratio3.82x
Sales growth 3y+29.5%Sector median +9.6%
Profit growth 3y+62.3%Sector median +13.3%
PEG1.26x
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹225 cr vs borrowings ₹26 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 141.2x in the last 12 months.
- Operating cash flow was below net profit in 4 of the last 5 years (FY26, FY25, FY23, FY22).
- Revenue was higher than a year earlier in 4 of the last 4 quarters.
- Other income was 7% of net profit in the last 12 months.
- Dividend paid in 4 of the last 5 financial years.
- Price ₹3,348.80 on 2026-10-26: -10.5% from the 52-week high, +113.3% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹3,659.60 · low ₹1,093.20
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 247 | 275 | 308 | 207 | 306 | 393 | 433 | 330 |
| EBITDA | 49 | 69 | 85 | 51 | 95 | 151 | 184 | 113 |
| OPM % | 19.8% | 25.0% | 27.5% | 24.6% | 31.1% | 38.3% | 42.4% | 34.3% |
| Other income | 8 | 2 | 6 | 16 | 10 | 5 | 11 | 2 |
| Net profit | 37 | 45 | 62 | 44 | 72 | 108 | 132 | 74 |
| EPS (₹) | 4.69 | 5.67 | 3.90 | 5.41 | 8.82 | 13.19 | 16.09 | 9.07 |
| Revenue YoY | +24.1% | +43.0% | +40.3% | +59.1% | ||||
| Profit YoY | +93.5% | +140.2% | +110.9% | +67.7% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 520 | 617 | 717 | 1,007 | 1,339 | 1,462 |
| EBITDA | 105 | 123 | 96 | 232 | 480 | 543 |
| Net profit | 72 | 83 | 43 | 159 | 356 | 386 |
| EPS (₹) | 10.52 | 11.43 | 5.83 | 9.90 | 43.51 | 47.17 |
| Revenue growth | +18.6% | +16.3% | +40.3% | +33.0% | +40.9% | |
| Profit growth | +15.8% | -48.6% | +271.1% | +124.5% | +104.3% | |
| Dividend / share (₹) | – | 3.00 | 3.00 | 3.00 | 1.50 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +29.5% | – | +40.9% |
| Net profit | +62.3% | – | +104.3% |
| EPS | +56.1% | – | – |
| Share price | – | – (2y) | +76.2% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 594 | 674 | 1,310 | 1,654 |
| Borrowings | – | 4 | 217 | 8 | 26 |
| Cash & equivalents | – | 59 | 53 | 249 | 225 |
| Total assets | – | 767 | 1,096 | 1,549 | 1,984 |
| Fixed assets | – | 222 | 360 | 505 | 633 |
| Capital work in progress | – | 26 | 125 | 130 | 332 |
| Investments | – | 2 | 0 | 0 | 0 |
| Receivables | – | 230 | 206 | 290 | 363 |
| Inventory | – | 119 | 157 | 180 | 231 |
| Payables | – | 142 | 135 | 156 | 154 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | -9 | 66 | 125 | 118 | 292 |
| Cash from investing | -124 | -33 | -365 | -224 | -266 |
| Cash from financing | 140 | -12 | 239 | 261 | 4 |
| Capex | 0 | 96 | 280 | 195 | 328 |
| Free cash flow | -9 | -31 | -155 | -76 | -36 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | 14.0% | 6.3% | 12.1% | 21.5% |
| ROCE % | – | 19.2% | 9.9% | 16.9% | 28.9% |
| Debtor days | – | 136 | 105 | 105 | 99 |
| Inventory days | – | 131 | 139 | 119 | 149 |
| Payable days | – | 157 | 119 | 103 | 99 |
| Cash conversion cycle (days) | – | 110 | 125 | 121 | 149 |
| Working capital days | – | 182 | 107 | 214 | 177 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 32.66% |
| FIIs | 22.62% |
| DIIs | 19.40% |
| of which Mutual funds | 14.44% |
| of which Insurance | 3.64% |
| Government | 0.01% |
| Public (non-institutions) | 25.31% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 35.96% | 35.96% | 32.66% | 32.66% | 32.66% | 32.66% | 32.66% | 32.66% |
| Promoter group | % |
|---|---|
| Nareshkumar Ramjibhai Patel | 17.69% |
| Vaghasia Chetankumar Chhaganlal | 14.97% |
| Gevriya Nileshkumar Bhikhubhai | 0.00% |
| Ramjibhai Limbabhai Patel | 0.00% |
| Arunaben Ramjibhai Patel | 0.00% |
| Meenaben Vijaybhai Dayani | 0.00% |
| Vijaybhai Gordhanbhai Dayani | 0.00% |
| Zumbeshkumar R Patel | 0.00% |
| Hirenkumar Vijayabhai Dayani | 0.00% |
| Sanketkumar R Patel | 0.00% |
| Bhanuben Chhaganbhai Vaghasia | 0.00% |
| Chhagan Ramjibhai Vaghasia | 0.00% |
| Nitaben Jigneshkumar Patel | 0.00% |
| Smita Sanjaykumar Thummer | 0.00% |
| Mukeshkumar Chhaganbhai Vaghasia | 0.00% |
| Public holders above 1% | % |
|---|---|
| Dhwani Girishkumar Chovatia | 3.35% |
| Government Pension Fund Global | 3.11% |
| Kotak Mahindra Trustee Co Ltd A/C Kotak Nifty Alpha 50 Index Fund | 2.86% |
| Axis MAX Life Insurance Limited A/C Nifty Momentum Quality 50 Fund | 2.04% |
| SBI Nifty Smallcap 250 Index Fund | 1.83% |
| Motilal Oswal Nifty Smallcap 250 Index Fund | 1.81% |
| Vanaja Sundar Iyer | 1.33% |
1,47,026 shareholders. Pledged: – of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| ACUTAAS | ₹27,417 cr | 71.0x | 16.6x | 26.1% | 31.7% | 37.1% | +29.5% | 0.05% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-09-17 | Dividend | Dividend - Rs 2.50 Per Share |
| 2025-09-18 | Dividend | Dividend - Rs 1.50 Per Share |
| 2025-04-25 | Split | Face Value Split (Sub-Division) - From Rs 10/- Per Share To Rs 5/- Per Share |
| 2024-09-13 | Other | Annual General Meeting |
| 2024-09-13 | Dividend | Dividend - Rs 3 Per Share |
| 2023-09-18 | Dividend | Dividend - Rs 3 Per Share |
| 2023-09-18 | Other | Annual General Meeting |
| 2022-07-29 | Dividend | Annual General Meeting/Dividend - Rs 3 Per Share |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Chemical Manufacturing: Manufacturing of Pharmaceutical Intermediates and Speciality chemicals
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | ACUTAAS |
| BSE code | 543349 |
| ISIN | INE00FF01025 |
| Face value | ₹5.0 |
| Incorporated | 2007-06-12 |
| Website | www.acutaas.com |
| Plants (India / abroad) | 3 / 1 |
From the company's filings (BRSR FY26).
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.